HC Wainwright Issues Positive Forecast for Vanda Pharmaceuticals (NASDAQ:VNDA) Stock Price

Vanda Pharmaceuticals (NASDAQ:VNDA) had its price objective hoisted by stock analysts at HC Wainwright from $18.00 to $20.00 in a report released on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price objective suggests a potential upside of 352.49% from the stock’s previous close.

Separately, StockNews.com began coverage on shares of Vanda Pharmaceuticals in a research note on Wednesday, February 5th. They issued a “hold” rating on the stock.

Vanda Pharmaceuticals Trading Down 6.0 %

VNDA stock opened at $4.42 on Tuesday. Vanda Pharmaceuticals has a 12-month low of $3.71 and a 12-month high of $6.75. The business’s 50-day moving average is $4.61 and its 200 day moving average is $4.84. The stock has a market cap of $257.73 million, a price-to-earnings ratio of -15.79 and a beta of 0.74.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.06. Vanda Pharmaceuticals had a negative return on equity of 3.02% and a negative net margin of 8.59%. The firm had revenue of $53.19 million for the quarter, compared to analyst estimates of $51.00 million. As a group, equities analysts forecast that Vanda Pharmaceuticals will post -0.32 EPS for the current fiscal year.

Hedge Funds Weigh In On Vanda Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in VNDA. Squarepoint Ops LLC increased its stake in shares of Vanda Pharmaceuticals by 186.4% in the 4th quarter. Squarepoint Ops LLC now owns 71,131 shares of the biopharmaceutical company’s stock worth $341,000 after acquiring an additional 46,293 shares during the last quarter. Two Sigma Advisers LP grew its holdings in shares of Vanda Pharmaceuticals by 11.2% in the fourth quarter. Two Sigma Advisers LP now owns 156,300 shares of the biopharmaceutical company’s stock valued at $749,000 after purchasing an additional 15,700 shares during the period. Two Sigma Investments LP increased its position in Vanda Pharmaceuticals by 94.7% during the fourth quarter. Two Sigma Investments LP now owns 199,460 shares of the biopharmaceutical company’s stock worth $955,000 after purchasing an additional 97,017 shares during the last quarter. Stonepine Capital Management LLC purchased a new position in Vanda Pharmaceuticals during the fourth quarter worth about $120,000. Finally, ProShare Advisors LLC boosted its holdings in Vanda Pharmaceuticals by 32.4% in the 4th quarter. ProShare Advisors LLC now owns 18,815 shares of the biopharmaceutical company’s stock valued at $90,000 after purchasing an additional 4,599 shares during the last quarter. Hedge funds and other institutional investors own 88.14% of the company’s stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.